Daiichi Sankyo has entered an agreement with Nitto Denko to use the latter’s proprietary PassPort active transdermal drug delivery technology, for the development of an undisclosed product of the former.
Pursuant to the agreement, Nitto Denko will support the clinical development of Daiichi Sankyo’s product and will be responsible for manufacturing and commercialisation of transdermal patches and device components associated with the product.
Go deeper with GlobalData
Discover B2B Marketing That Performs
Combine business intelligence and editorial excellence to reach engaged professionals across 36 leading media platforms.
Trianni and LakePharma have signed a co-development agreement to conduct in-vivo discovery of human monoclonal therapeutics to increase antibody diversity and quality, by employing Trianni’s mouse platform for antibody discovery services.
The partnership grants the rights for utilisation and marketing of Trianni mouse platform services to Lakepharma.
Aptinyx plans to advance initial clinical studies of its lead drug candidates and the discovery of small molecule modulators of the NMDA receptor, through the funds raised from a series A venture financing.
The financing round was led by New Leaf Venture partners with the support of Fraizer Healthcare, Longitude Capital management, Osage University Partners, Adams Street Partners, LVP Life Science Ventures, PathoCapital, Goudy Park Capital, Beecken Petty O’Keefe & Company and Northwestern University.
US Tariffs are shifting - will you react or anticipate?
Don’t let policy changes catch you off guard. Stay proactive with real-time data and expert analysis.
By GlobalDataThe company has raised gross proceeds of $65m from the financing round.
AstraZeneca expects to raise funds up to $2.51bn through the public offering of notes under a $5bn Euro Medium Term Notes programme. The proceeds will be used for general corporate purposes.
The company has announced to issue the notes to investors outside the US at an interest of 0.75% for eight-year fixed-rate notes, 1.25% for 12-year fixed-rate notes and 0.25% for five-year fixed-rate notes.
Chiesi Farmaceutici has entered a definitive agreement with The Medicine Company (TMC) to acquire the latter’s Cleviprex (Clevidipine), Kengreal (cangrelor) and the rights to Argatroban injection for a sale consideration of $792m.
Goldman, Sachs and Co. is acting as the financial advisor and Cadwalader, Wickersham & Taft LLP is acting as legal advisor for the target company.
The agreement enables the two companies to further develop and expand their product pipeline and portfolio.
Image: Nitto Denko will support the clinical development of Daiichi Sankyo’s product. Photo: Courtesy of KishujiRapid.
